Transaction overview
Thermo Fisher Scientific, a U.S.-based leader in analytical instruments, laboratory equipment, and life sciences solutions, acquired Olink Holding, a Swedish precision proteomics company, on October 17, 2023, for $3.1 billion. The deal represents Thermo Fisher's commitment to expanding its capabilities in protein analysis through the integration of Olink’s high-throughput technology.
Deal structure and financing
The acquisition was structured as an all-cash transaction with no specific equity or debt split disclosed publicly. Lead investment banks advising on the deal were Evercore and Barclays for Thermo Fisher, alongside Baird for Olink Holding. While leverage metrics are not specified in public announcements, it is typical of such deals that significant financing would come from a combination of cash reserves, new debt issuance, and potentially existing credit facilities.
No lock-up terms or IPO optionality details have been publicly shared regarding the transaction’s financial structure. Additionally, there is no information available on whether any equity stake was retained by Olink Holding's sellers post-transaction.
Strategic context
Thermo Fisher’s rationale for acquiring Olink Holding centers on enhancing its portfolio with cutting-edge protein analysis technology that complements existing mass spectrometry and life sciences platforms. This acquisition aims to strengthen Thermo Fisher’s position in the rapidly evolving field of proteomics, enabling it to offer more comprehensive solutions to researchers studying complex biological systems.
For Olink Holding, divesting to a larger player like Thermo Fisher provides an opportunity for accelerated growth through access to broader market reach and integration with advanced instrumentation. Historical context suggests this deal is part of a trend where smaller biotech companies partner or are acquired by industry giants seeking to expand their technological scope and operational scale.
Regulatory path
The transaction required review by antitrust regulators in the United States, as well as likely scrutiny from European Union authorities given Thermo Fisher’s extensive international operations. As of October 17, 2023, there were no public disclosures about specific regulatory remedies or delays imposed on the deal due to competition concerns. The parties would have submitted Hart-Scott-Rodino (HSR) filings in the U.S., and EU Merger Notification documents, around September 2023 to meet statutory deadlines before closing.